Poolbeg Pharma (POLB) News Today GBX 3.95 -0.85 (-17.71%) As of 02/21/2025 11:46 AM Eastern Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsHeadlinesInsider Trades All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 Time Period Poolbeg Pharma shares plummet as Hookipa walks away from possible bidFebruary 21 at 4:29 AM | lse.co.ukPoolbeg Agrees to Bid Deadline Extension for Possible Hookipa Pharma DealJanuary 30, 2025 | marketwatch.comGilead gives its blessing to Poolbeg Pharma’s Hookpia merger dealJanuary 7, 2025 | msn.comPoolbeg Pharma to merge with Austrian biotech companyJanuary 2, 2025 | msn.comHookipa Pharma to acquire Poolbeg PharmaJanuary 2, 2025 | msn.comPoolbeg Pharma’s POLB 001 Shows Promise in CRS TreatmentDecember 9, 2024 | markets.businessinsider.comPoolbeg Pharma granted US patent for influenza treatmentNovember 21, 2024 | lse.co.ukPoolbeg Pharma Share Chat (POLB)October 30, 2024 | lse.co.uk2 exciting penny stocks under 20p to consider buying todaySeptember 15, 2024 | msn.comPoolbeg Pharma PLC (7JN.F)August 23, 2024 | uk.finance.yahoo.comPoolbeg Pharma PLC Announces Voluntary Delisting from OTCQB MarketJuly 26, 2024 | finance.yahoo.comThis 13p penny stock’s on fire! Should I buy it?May 15, 2024 | msn.comPoolbeg Pharma (LON:POLB) Trading 17.3% Higher Poolbeg Pharma (LON:POLB) Trading 17.3% HigherMay 7, 2024 | marketbeat.comPoolbeg Pharma celebrates full patent approval for Immunomodulator IIMay 1, 2024 | lse.co.ukPoolbeg Pharma and Silk Road Therapeutics announce strategic collaboration on novel orphan drugMay 1, 2024 | finance.yahoo.comPoolbeg Pharma PLC Announces Significant POLB 001 Patent Granted in USAMay 1, 2024 | finance.yahoo.comPoolbeg Pharma (LON:POLB) Sets New 1-Year High at $12.20Poolbeg Pharma (LON:POLB) Hits New 1-Year High at $12.20April 30, 2024 | marketbeat.comPoolbeg Pharma PLC Announces Results for the Year Ended 31 December 2023April 30, 2024 | finance.yahoo.comPoolbeg Pharma PLC Announces TR-1: Notification of Major HoldingsApril 29, 2024 | finance.yahoo.comFavourable Signals For Poolbeg Pharma: Numerous Insiders Acquired StockMarch 27, 2024 | finance.yahoo.comPoolbeg Pharma moves closer to locking down IP protection for key...March 20, 2024 | proactiveinvestors.comPoolbeg Pharma PLC Announces Director/PDMR ShareholdingFebruary 22, 2024 | finance.yahoo.comPoolbeg Pharma chair discusses shift to executive role; hVIVO share saleFebruary 20, 2024 | finance.yahoo.comPoolbeg Pharma PLC Announces Director Share PurchaseFebruary 19, 2024 | finance.yahoo.comWe Think Poolbeg Pharma (LON:POLB) Can Afford To Drive Business GrowthFebruary 15, 2024 | finance.yahoo.comPoolbeg Pharma announces board role change and launch of EIPFebruary 15, 2024 | msn.comPoolbeg Pharma PLC Announces Board Role Change and Launch of EIPFebruary 15, 2024 | finance.yahoo.comPoolbeg Pharma says research confirms $10B plus opportunity for POLB 001 in cancer immunotherapiesFebruary 12, 2024 | finance.yahoo.comPoolbeg Pharma PLC Announces Market Opportunity for POLB 001 for CRSFebruary 12, 2024 | finance.yahoo.comPoolbeg Pharma's new VP of Clinical Operations Laura Maher aims to help progress development assetsFebruary 8, 2024 | finance.yahoo.comPoolbeg Pharma PLC Announces Further Data Shows POLB001 Potential in Cancer CRSJanuary 17, 2024 | finance.yahoo.comPoolbeg Pharma identifies promising RSV drug candidates as part of AI-led programmeDecember 20, 2023 | msn.comPoolbeg Pharma PLC Announces RSV AI Drug Candidate Analysis UpdateDecember 20, 2023 | finance.yahoo.comPoolbeg Pharma PLC Announces POLB 001 Data Presented at ASHDecember 11, 2023 | finance.yahoo.comPoolbeg Pharma non-exec steps down from boardNovember 30, 2023 | proactiveinvestors.comPoolbeg Pharma PLC Announces Directorate ChangeNovember 30, 2023 | finance.yahoo.comTRADING UPDATES: Poolbeg hails approval; EDX links with Thermo FisherNovember 21, 2023 | lse.co.ukPoolbeg Pharma lands Japanese patent grant for lead assetNovember 21, 2023 | proactiveinvestors.comPoolbeg Pharma PLC Announces Immunomodulator II Patent Granted in JapanNovember 21, 2023 | finance.yahoo.comFormer Amryt Pharma Leadership Team join PoolbegNovember 9, 2023 | finance.yahoo.comPoolbeg Pharma "continuing its campaign to find a partner" for POLB001November 2, 2023 | finance.yahoo.comPoolbeg investor meeting will take a deep dive into lead programmeNovember 1, 2023 | proactiveinvestors.comPoolbeg Pharma PLC Announces POLB 001 Oncology Programme Update MeetingNovember 1, 2023 | finance.yahoo.comPoolbeg advisory board endorses flu drug approachOctober 26, 2023 | proactiveinvestors.comPoolbeg Pharma unveils new collaboration agreementOctober 17, 2023 | proactiveinvestors.comPoolbeg Partners with a Nasdaq-Listed BiopharmaOctober 17, 2023 | finance.yahoo.comPoolbeg Pharma PLC Announces Favourable Conclusion of Patent OppositionSeptember 29, 2023 | finance.yahoo.comPoolbeg Pharma shores up protection around its IPSeptember 20, 2023 | proactiveinvestors.comPoolbeg Pharma: Third party withdraws patent oppositionSeptember 19, 2023 | proactiveinvestors.comPoolbeg Pharma PLC Announces Immunomodulator I Patent Opposition WithdrawalSeptember 19, 2023 | finance.yahoo.com Get Poolbeg Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for POLB and its competitors with MarketBeat's FREE daily newsletter. Email Address POLB Media Mentions By Week POLB Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. POLB News Sentiment▼0.300.60▲Average Medical News Sentiment POLB News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. POLB Articles This Week▼10▲POLB Articles Average Week Get Poolbeg Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for POLB and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies SCLP News Today REDX News Today ETX News Today FUM News Today SAR News Today AREC News Today IMM News Today OPTI News Today FAB News Today ONC News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (LON:POLB) was last updated on 2/22/2025 by MarketBeat.com Staff From Our PartnersBuy NVDA Now? After weeks of volatility, did President Trump just turn Nvidia (NVDA) into a raging BUY? The beloved chip...Chaikin Analytics | SponsoredSecret financial plot unfolding in Washington DC… [DEVELOPING]What stocks are next up to soar in 2025? I believe I’ve found the answer - and it might surprise you. Yo...Timothy Sykes | SponsoredElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredWe recommended Palantir in 2021, now we’re recommending this...I believe it could offer you a MAJOR boost to your retirement. And it pays huge dividends to give you a nic...Behind the Markets | SponsoredBuy this AI Stock Before Elon’s AnnouncementWith Trump back in office, xAI is primed to become the leader in generative AI, leaving competitors in the dus...InvestorPlace | SponsoredMarket down? Do this now.During Trump's first term, his tariffs sent gold prices soaring. Investors who acted early made a fortune. Now...Colonial Metals | SponsoredThis Crypto Is Set to Explode in FebruaryIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Poolbeg Pharma PLC Please log in to your account or sign up in order to add this asset to your watchlist. Share Poolbeg Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
